
Pulse Biosciences (PLSE) Stock Forecast & Price Target
Pulse Biosciences (PLSE) Analyst Ratings
Bulls say
Pulse Biosciences is attractive fundamentally because it has a differentiated, patent-protected nsPFA platform with over 250 issued patents and strong early feasibility data, including 100% procedural success at six months and 96.2% at 12 months in 141 patients, which supports the case that its technology could be safer and faster than traditional PFA. The company is also de-risking execution through rapid pivotal-trial progress, with NANOPULSE-AF enrollment completed in October and NANOCLAMP-AF expected to finish in mid-2027, while CE mark approval is expected in 4Q27 and multiple FDA milestones could follow in 2028. Financially, it remains pre-revenue in EP but had about $189 million of cash at the end of 3Q26 after using $15.3 million in the quarter, and its already-cleared Vybrance business plus partnership opportunities provide a capital-efficient path to commercialization across large addressable markets.
Bears say
Pulse Biosciences is facing a negative setup because 3Q26 revenue of $0.4M missed consensus and GAAP EPS of ($0.32) slightly underperformed, while estimates were trimmed to $1.8M for 2026 and $7.2M for 2027, underscoring limited near-term commercial traction. The company remains highly exposed to clinical and regulatory risk, with the NANOPULSE-AF pivotal study still a key catalyst and any delay or weaker-than-feasibility outcomes potentially undermining approval, sentiment, and partnership prospects. Despite $101.6M in cash at the end of the second quarter of 2026, cash burn is expected to rise to ~$77M in 2026, and absent a strategic partner or stronger revenue, continued equity financing could prove dilutive.
This aggregate rating is based on analysts' research of Pulse Biosciences and is not a guaranteed prediction by Public.com or investment advice.
Pulse Biosciences (PLSE) Analyst Forecast & Price Prediction
Start investing in Pulse Biosciences (PLSE)
Order type
Buy in
Order amount
Est. shares
0 shares
FAQs About Pulse Biosciences (PLSE) Forecast
Pulse Biosciences (PLSE) Analyst Forecast & Price Prediction
Start investing in Pulse Biosciences (PLSE)
Order type
Buy in
Order amount
Est. shares
0 shares